We have been involved

in a large number of transactions
across a wide spectrum of industries

Farlie Turner Advises Clinical Trial Services Company in Recapitalization with Five Points Capital

By: Farlie Turner - Date: 01/17/2019

FORT LAUDERDALE, Fla. (January 17, 2018) – Farlie Turner & Co. (“Farlie Turner”), a leading investment bank serving middle market clients, is pleased to announce that it advised a healthcare services company in a recapitalization transaction with Five Points Capital. Terms of the transaction were not disclosed.

The Company is a leading clinical trial site specializing in research dedicated to the treatment of central nervous system disorders. The Company consistently ranks among the top enrolling sites for the trials in which it participates, and is trusted by global pharmaceutical companies, biotech firms and clinical research organizations for its expertise in trial design and enrollment.

“We are very pleased to have represented such a high-quality company in this important healthcare niche,” commented Managing Director Craig Farlie. “Our healthcare services practice continues to achieve extraordinary results for our clientele, and we are pleased to have brought our client an outstanding partner to fuel the company’s continued growth.”

The Farlie Turner transaction team was led by Managing Director Craig Farlie and Director Daniel Vetrano, with Chris Henry also playing a key role.

About Farlie Turner

Farlie, Turner & Co., LLC, and its affiliate Bayshore Partners, LLC, a broker-dealer registered with FINRA, provide merger and acquisition, private placement and financial advisory services to middle market companies. Please visit www.farlieturner.com for more information.

 


Go to Top

© 2019 Farlie Turner & Co. | All rights reserved
Bayshore Partners, LLC is an affiliate of Farlie Turner and a member of FINRA & SIPC.
All merger and acquisition and private placement transactions involving securities are conducted through Bayshore Partners, LLC.